Measures · D12 in 2026 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Statin Use in Persons with Diabetes (SUPD)
Drug PlanMedication AdherenceSource: Prescription Drug Events
- What it measures
- To lower their risk of developing heart disease, most people with diabetes should take cholesterol medication. This rating is based on the percent of plan members with diabetes who take the most effective cholesterol-lowering drugs. Plans can help make sure their members get these prescriptions filled.
- How it's calculated
- This measure is defined as the percentage of Medicare Part D beneficiaries, 40-75 years old, who were dispensed at least two diabetes medication fills on unique dates of service and received a statin medication fill during the measurement period. The index prescription start date (IPSD) is the earliest date of service for a diabetes medication during the measurement year. Continuous enrollment (CE) is defined as being continuously enrolled in a Medicare Part D contract during the measurement period, with one allowable gap in enrollment of up to one calendar month. Beneficiaries are only included in the measure calculation if the IPSD occurs at least 90 days before the end of the measurement period. The percentage is calculated as the number of continuously enrolled beneficiaries, 40- 75 years old, who received a statin medication fill during the measurement period (numerator) divided by the number of continuously enrolled beneficiaries, 40-75 years old, with at least two diabetes medication fills on unique dates of service during the measurement period and an IPSD that occurs at least 90 days prior to the end of the measurement period (denominator). The SUPD measure is adapted from the measure concept that was developed and endorsed by the PQA. See the medication list for this measure. The SUPD measure is calculated using the NDC lists updated by the PQA. The complete NDC lists, including diagnosis codes, are posted along with these technical notes.
- Data source
- Prescription Drug Event (PDE) data The data for this measure come from Prescription Drug Event (PDE) data submitted by drug plans to the CMS DDPS and accepted by the 2024 PDE submission deadline for annual Part D payment reconciliation with dates of service from January 1, 2024 – December 31, 2024. If the PDE edit results in the PDE being rejected by DDPS, then the PDE is not used in the Patient Safety measure calculations. If the PDE edit is informational and therefore does not result in the PDE being rejected, then the PDE is used in the Patient Safety measure calculations. Reminder, CMS uses the term “final action” PDE to describe the most recently accepted original, adjustment, or deleted PDE record representing a single dispensing event. Original and adjustment final action PDEs submitted by the sponsor and accepted by DDPS prior to the 2024 PDE submission deadline are used to calculate this measure. PDE adjustments made post- reconciliation were not reflected in this measure. Additional data sources include the CME, the CWF, and the EDS. The data cutoff date for all the additional data sources listed below such as the CME, CWF, and EDS is determined by the same PDE submission deadline for the annual Part D payment reconciliation. • CME is used for enrollment information and to identify beneficiaries who elected to receive hospice care or with ESRD status (dialysis start and end dates within the measurement period). • CWF is used to identify exclusion diagnoses based on ICD-10-CM codes. • EDS is used to identify exclusion diagnoses based on ICD-10-CM codes.
- Measurement period
- 01/01/2024 – 12/31/2024
- Better when
- Higher
- Weight
- 1 (Process Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- No
- In improvement measure
- Yes
- Used in CAI
- Yes
- Exclusions
Show
Contracts with 30 or fewer continuously enrolled beneficiaries (in the denominator). The following beneficiaries are excluded from the denominator if at any time during the measurement period: • Hospice enrollment • ESRD diagnosis or dialysis coverage dates • Rhabdomyolysis and Myopathy • Pregnancy, Lactation, and Fertility • Cirrhosis • Pre-Diabetes • Polycystic Ovary Syndrome- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the PQA medication or NDC lists, are excluded from CMS analyses.
- Disaster policy
- Higher measure star (2025-2026) for contracts with 25% or more enrolled affected by 2024 disasters. Meaningful Measure Chronic Conditions Area:
From the 2026 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 83 | 84.5 | +1.5 |
| 3★ | MA-PD | 87 | 89 | +2 |
| 4★ | MA-PD | 90 | 91 | +1 |
| 5★ | MA-PD | 94 | 95 | +1 |
| 2★ | PDP | 81 | 82.5 | +1.5 |
| 3★ | PDP | 83 | 83.5 | +0.5 |
| 4★ | PDP | 85 | 85.5 | +0.5 |
| 5★ | PDP | 87 | 88 | +1 |
2026 star distribution
Not rated: Plan too new to be measured (93); Not enough data available (61); Plan not required to report measure (8)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 83 % | >= 83 % to < 87 % | >= 87 % to < 90 % | >= 90 % to < 94 % | >= 94 % |
| 2027 | PDP | < 81 % | >= 81 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2026 | MA-PD | < 81 % | >= 81 % to < 85 % | >= 85 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2026 | PDP | < 82 % | >= 82 % to < 83 % | >= 83 % to < 84 % | >= 84 % to < 86 % | >= 86 % |
| 2025 | MA-PD | < 81 % | >= 81 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2025 | PDP | < 80 % | >= 80 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2024 | MA-PD | < 81 % | >= 81 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 92 % | >= 92 % |
| 2024 | PDP | < 81 % | >= 81 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2023 | MA-PD | < 80 % | >= 80 % to < 84 % | >= 84 % to < 86 % | >= 86 % to < 90 % | >= 90 % |
| 2023 | PDP | < 80 % | >= 80 % to < 82 % | >= 82 % to < 84 % | >= 84 % to < 86 % | >= 86 % |
| 2022 | MA-PD | < 76 % | >= 76 % to < 80 % | >= 80 % to < 84 % | >= 84 % to < 88 % | >= 88 % |
| 2022 | PDP | < 77 % | >= 77 % to < 79 % | >= 79 % to < 82 % | >= 82 % to < 84 % | >= 84 % |
| 2021 | MA-PD | < 77 % | >= 77 % to < 81 % | >= 81 % to < 83 % | >= 83 % to < 87 % | >= 87 % |
| 2021 | PDP | < 74 % | >= 74 % to < 79 % | >= 79 % to < 82 % | >= 82 % to < 85 % | >= 85 % |
| 2020 | MA-PD | < 74% | ? 74% to < 78% | ? 78% to < 81% | ? 81% to < 83% | ? 83% |
| 2020 | PDP | < 76% | ? 76% to < 78% | ? 78% to < 79% | ? 79% to < 83% | ? 83% |
| 2019 | MA-PD | < 72% | ? 72% to < 76% | ? 76% to < 80% | ? 80% to < 83% | ? 83% |
| 2019 | PDP | < 73% | ? 73% to < 77% | ? 77% to < 79% | ? 79% to < 82% | ? 82% |
Lowest-scoring contracts, 2026
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| H1526 Gold Kidney Health Plan | Gold Kidney Health Plan | 3,058 | 70 | 1 | — | 19 | 0% |
| S5795 Arkansas Blue Medicare | USAble Mutual Insurance Company | 19,195 | 79 | 1 | 0 | 5 | 0% |
| H7779 American Health Advantage of Tennessee | Mitchell Family Office | 297 | 72 | 1 | 0 | 17 | 0% |
| H6743 ATRIO Health Plans | ATRIO Health Plans | 21,042 | 77 | 1 | 0 | 12 | 0% |
| H3810 AllCare Advantage | AllCare Health, Inc. | 2,485 | 77 | 1 | 0 | 12 | 0% |
| H2926 PrimeWest Health | PrimeWest Rural MN Health Care Access Initiative | 749 | 77 | 1 | 0 | 12 | 0% |
| H9489 Vermont Blue Advantage | Blue Cross Blue Shield of Michigan Mutual Ins. Co. | 0 | 77 | 1 | 0 | 12 | 0% |
| H8947 Peak Health | West Virginia United Health System, Inc. | 12,866 | 77 | 1 | — | 12 | 0% |
| H1347 Patrius Health | BlueCross BlueShield of Alabama | 4,544 | 78 | 1 | — | 11 | 1% |
| H1350 Blue Cross of Idaho | Gemstone Holdings, Inc. | 32,406 | 78 | 1 | 0 | 11 | 1% |
| H4232 American Health Advantage of Utah | Mitchell Family Office | 296 | 78 | 1 | 0 | 11 | 1% |
| H6202 NextBlue of North Dakota | Blue Cross Blue Shield of Michigan Mutual Ins. Co. | 6,709 | 79 | 1 | 0 | 10 | 2% |
| H1304 Regence BlueShield of Idaho | Cambia Health Solutions, Inc. | 902 | 79 | 1 | 0 | 10 | 2% |
| H4213 Arkansas Blue Medicare | USAble Mutual Insurance Company | 2,258 | 79 | 1 | 0 | 10 | 2% |
| H3251 Blue Cross and Blue Shield of New Mexico | Health Care Service Corporation | 19,880 | 79 | 1 | −1 | 10 | 2% |
| H5435 UnitedHealthcare | UnitedHealth Group, Inc. | 1,420 | 79 | 1 | −1 | 10 | 2% |
| H3814 ATRIO Health Plans | ATRIO Health Plans | 1,997 | 79 | 1 | 0 | 10 | 2% |
| H8095 Wellmark Advantage Health Plan | Blue Cross Blue Shield of Michigan Mutual Ins. Co. | 0 | 79 | 1 | −1 | 10 | 2% |
| R6694 Aetna Medicare | CVS Health Corporation | 899 | 79 | 1 | −1 | 10 | 2% |
| H6851 WellSense Health Plan | BMC Health System, Inc. | 4,226 | 79 | 1 | 0 | 10 | 2% |
| H9699 Arkansas Blue Medicare | USAble Mutual Insurance Company | 7,909 | 79 | 1 | −1 | 10 | 2% |
| H6379 Clear Spring Health | Group 1001 | — | 79 | 1 | — | 10 | 2% |
| S5726 Blue Cross and Blue Shield of Kansas | Blue Cross Blue Shield of Kansas | 153,378 | 80 | 1 | −1 | 4 | 3% |
| S1030 BlueRx (PDP) | BlueCross BlueShield of Alabama | 30,843 | 80 | 1 | −1 | 4 | 3% |
| H9042 MyTruAdvantage | SIHO Holding, Inc. | 8,659 | 80 | 1 | −1 | 9 | 4% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D11 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2025 – 12/31/2025 | 1 | Prescription Drug Events |
| 2026 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2024 – 12/31/2024 | 1 | Prescription Drug Events |
| 2025 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2023 – 12/31/2023 | 1 | Prescription Drug Events |
| 2024 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2022 – 12/31/2022 | 1 | Prescription Drug Events |
| 2023 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2021 – 12/31/2021 | 1 | Prescription Drug Events |
| 2022 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2020 – 12/31/2020 | 3 | Prescription Drug Events |
| 2021 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2019 – 12/31/2019 | 3 | Prescription Drug Events |
| 2020 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2018 – 12/31/2018 | 1 | Prescription Drug Events |
| 2019 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2017 – 12/31/2017 | 1 | Prescription Drug Events |